Caplin Point Laboratories Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Reporting (BRSR)'.
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Caplin Point Laboratories has submitted its BRSR report for FY 2024-25 under SEBI's listing regulations. The company is a 100% export-oriented pharmaceutical manufacturer, serving 551 countries with a turnover of ₹752.41 crore and net worth of ₹1,700.93 crore. It operates 3 manufacturing units and 5 R&D centers with 2,938 total employees (including workers), and reports subsidiaries Caplin Steriles (99.999%) and Caplin One Labs (100%). The report highlights ESG progress including Zero Liquid Discharge at the COL facility, increased renewable energy use through investment in Thangamman Renewable Energy, and operationalization of the Caplin Point Meenakshi Hospital under CSR. The company reported no fines, penalties, or complaints related to corruption or bribery, and complies with US FDA, WHO GMP, and ISO 9001 standards. Employee turnover rose from 26.9% to 32.52% year-on-year.
This is a mandatory annual ESG disclosure with no direct impact on earnings or dividends. The report reflects a clean compliance record and ongoing sustainability investments, which may support the company's reputation with institutional investors focused on ESG, though no material business change is signaled.